AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 178 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $131,034 | -7.9% | 5,294 | +5.4% | 0.00% | – |
Q2 2023 | $142,225 | -38.7% | 5,022 | -50.3% | 0.00% | – |
Q1 2023 | $231,956 | -99.5% | 10,098 | -99.4% | 0.00% | -100.0% |
Q4 2022 | $46,060,026 | -14.6% | 1,640,314 | -14.0% | 0.01% | -16.7% |
Q3 2022 | $53,919,000 | -17.2% | 1,906,554 | -35.1% | 0.01% | 0.0% |
Q2 2022 | $65,088,000 | -53.6% | 2,935,842 | -39.1% | 0.01% | -45.5% |
Q1 2022 | $140,266,000 | -21.5% | 4,818,492 | -11.3% | 0.01% | -15.4% |
Q4 2021 | $178,626,000 | -43.5% | 5,434,314 | -20.7% | 0.01% | -48.0% |
Q3 2021 | $316,074,000 | -29.0% | 6,848,818 | -15.3% | 0.02% | -28.6% |
Q2 2021 | $445,400,000 | +9.5% | 8,082,010 | +2.6% | 0.04% | 0.0% |
Q1 2021 | $406,867,000 | +116.4% | 7,878,905 | +81.6% | 0.04% | +105.9% |
Q4 2020 | $187,994,000 | +40.3% | 4,338,667 | +13.3% | 0.02% | +21.4% |
Q3 2020 | $134,011,000 | -55.4% | 3,828,886 | -31.8% | 0.01% | -57.6% |
Q2 2020 | $300,361,000 | -5.9% | 5,616,327 | -37.6% | 0.03% | -25.0% |
Q1 2020 | $319,163,000 | -24.3% | 8,995,579 | +1.9% | 0.04% | -6.4% |
Q4 2019 | $421,559,000 | +47.6% | 8,828,462 | +0.2% | 0.05% | +38.2% |
Q3 2019 | $285,539,000 | -35.0% | 8,812,932 | +0.1% | 0.03% | -33.3% |
Q2 2019 | $439,278,000 | -25.6% | 8,806,700 | +0.5% | 0.05% | -28.2% |
Q1 2019 | $590,728,000 | +46.8% | 8,759,313 | +0.4% | 0.07% | +29.1% |
Q4 2018 | $402,393,000 | -40.0% | 8,726,801 | +0.3% | 0.06% | -26.7% |
Q3 2018 | $670,858,000 | -7.8% | 8,698,886 | +0.7% | 0.08% | -10.7% |
Q2 2018 | $727,818,000 | +3.5% | 8,640,843 | +0.5% | 0.08% | +1.2% |
Q1 2018 | $703,227,000 | +68.3% | 8,599,011 | +17.6% | 0.08% | +69.4% |
Q4 2017 | $417,898,000 | -13.7% | 7,309,743 | +0.7% | 0.05% | -16.9% |
Q3 2017 | $484,517,000 | +30.3% | 7,258,679 | +0.4% | 0.06% | +28.3% |
Q2 2017 | $371,846,000 | +0.6% | 7,227,331 | +14.1% | 0.05% | -2.1% |
Q1 2017 | $369,774,000 | +40.7% | 6,331,747 | +0.5% | 0.05% | +34.3% |
Q4 2016 | $262,849,000 | -19.9% | 6,298,816 | +1.4% | 0.04% | -20.5% |
Q3 2016 | $328,069,000 | +37.7% | 6,211,072 | +9.3% | 0.04% | +33.3% |
Q2 2016 | $238,163,000 | +3.4% | 5,684,768 | +0.2% | 0.03% | +3.1% |
Q1 2016 | $230,368,000 | -37.2% | 5,674,084 | +0.5% | 0.03% | -34.7% |
Q4 2015 | $366,544,000 | -7.5% | 5,646,095 | +0.5% | 0.05% | -12.5% |
Q3 2015 | $396,472,000 | -36.2% | 5,616,553 | +0.4% | 0.06% | -30.0% |
Q2 2015 | $621,798,000 | +18.1% | 5,594,725 | +0.2% | 0.08% | +19.4% |
Q1 2015 | $526,455,000 | -14.5% | 5,582,768 | +1.6% | 0.07% | -16.2% |
Q4 2014 | $615,587,000 | +91.1% | 5,494,348 | +4.6% | 0.08% | +81.8% |
Q3 2014 | $322,116,000 | +38.1% | 5,250,459 | +3.1% | 0.04% | +41.9% |
Q2 2014 | $233,299,000 | +63.7% | 5,091,646 | +39.9% | 0.03% | +55.0% |
Q1 2014 | $142,533,000 | +166.7% | 3,640,679 | +63.1% | 0.02% | +150.0% |
Q4 2013 | $53,446,000 | -14.3% | 2,231,565 | 0.0% | 0.01% | -20.0% |
Q3 2013 | $62,395,000 | – | 2,231,565 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rock Springs Capital Management LP | 2,661,605 | $61,137,067 | 1.46% |
Bellevue Group AG | 4,013,500 | $92,190,095 | 1.34% |
Eagle Health Investments LP | 267,630 | $6,147,461 | 1.20% |
ARMISTICE CAPITAL, LLC | 3,460,000 | $79,476,200 | 1.14% |
Integral Health Asset Management, LLC | 213,000 | $4,892,610 | 0.99% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 454,000 | $10,428,380 | 0.44% |
ArrowMark Colorado Holdings LLC | 1,557,705 | $35,780,484 | 0.41% |
FARALLON CAPITAL MANAGEMENT LLC | 2,092,829 | $48,072,282 | 0.27% |
Virtus ETF Advisers LLC | 9,932 | $228,138 | 0.13% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 614,533 | $14,115,823 | 0.09% |